Chembio Diagnostics - Stock Price History | CEMI

Historical daily share price chart and data for Chembio Diagnostics since 2019 adjusted for splits. The latest closing stock price for Chembio Diagnostics as of December 06, 2019 is 3.94.
  • The all-time high Chembio Diagnostics stock closing price was 16.00 on June 15, 2004.
  • The Chembio Diagnostics 52-week high stock price is 7.90, which is 100.5% above the current share price.
  • The Chembio Diagnostics 52-week low stock price is 3.80, which is 3.6% below the current share price.
  • The average Chembio Diagnostics stock price for the last 52 weeks is 6.08.
Chembio Diagnostics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2018 8.7806 8.1000 11.5000 4.9500 5.6600 -30.98%
2017 6.2502 6.6500 8.3500 5.2500 8.2000 20.59%
2016 6.7890 5.2100 9.1200 4.2800 6.8000 27.58%
2015 4.5294 3.8700 5.3400 3.5600 5.3300 36.32%
2014 3.5915 3.4000 4.7300 2.8700 3.9100 16.02%
2013 4.4190 4.7501 5.7100 3.2900 3.3700 -28.75%
2012 4.3034 3.4400 5.2599 3.2800 4.7300 40.77%
2011 3.4753 3.2800 4.5600 2.4800 3.3600 -1.18%
2010 2.1713 2.1600 3.6400 1.5200 3.4000 51.79%
2009 1.3250 0.8800 2.9600 0.6400 2.2400 154.55%
2008 1.3837 1.9200 2.4000 0.6000 0.8800 -59.26%
2007 4.6029 6.1600 7.2000 2.1600 2.1600 -67.47%
2006 5.8140 3.0400 8.2400 2.6400 6.6400 137.14%
2005 4.8378 5.7600 6.5600 2.4400 2.8000 -51.39%
2004 10.2441 9.2000 16.0000 4.8000 5.7600 0.00%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.069B $0.033B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $151.583B 20.94
Abbott Laboratories (ABT) United States $151.168B 27.57
Stryker (SYK) United States $76.313B 25.66
Boston Scientific (BSX) United States $61.440B 29.00
Baxter (BAX) United States $42.463B 25.75
Essilor Luxottica (ESLOY) France $33.468B 0.00
Zimmer Biomet Holdings (ZBH) United States $30.550B 19.17
Terumo (TRUMY) Japan $27.062B 0.00
Lonza Group Ag (LZAGY) Switzerland $25.531B 0.00
Coloplast (CLPBY) Denmark $25.294B 39.03
ResMed (RMD) United States $21.653B 39.94
Smith & Nephew SNATS (SNN) United Kingdom $19.279B 0.00
Sunny Optical Technology (SNPTF) China $19.151B 0.00
Insulet (PODD) United States $11.373B 541.06
Bio-Rad Laboratories (BIO) United States $11.201B 53.76
DiaSorin S.p.A (DSRLF) Italy $7.616B 0.00
William Demant Holdings (WILYY) Denmark $7.531B 0.00
Hill-Rom Holdings (HRC) United States $7.203B 21.24
Perrigo (PRGO) Ireland $7.117B 13.27
Canopy Growth (CGC) Canada $6.501B 0.00
Haemonetics (HAE) United States $6.146B 41.53
Shandong Weigao Medical Polymer (SHWGF) China $5.743B 0.00
GN STORE NORD (GNNDY) Denmark $5.276B 0.00
NuVasive (NUVA) United States $3.890B 30.64
ICU Medical (ICUI) United States $3.830B 24.97
Neogen (NEOG) United States $3.545B 59.33
Hutchison China MediTech (HCM) Hong Kong, SAR China $3.165B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.121B 0.00
Quidel (QDEL) United States $2.954B 28.04
Aurora Cannabis (ACB) Canada $2.648B 0.00
National Vision Holdings (EYE) United States $2.432B 54.89
Agios Pharmaceuticals (AGIO) United States $2.411B 0.00
Cardiovascular Systems (CSII) United States $1.577B 0.00
InMode (INMD) Israel $1.516B 0.00
AtriCure (ATRC) United States $1.226B 0.00
Aphria (APHA) $1.187B 0.00
VAREX IMAGING (VREX) United States $1.162B 23.28
Phibro Animal Health (PAHC) United States $0.994B 18.61
NanoString Technologies (NSTG) United States $0.944B 0.00
Lantheus Holdings (LNTH) United States $0.802B 20.04
Eagle Pharmaceuticals (EGRX) United States $0.771B 29.55
TG Therapeutics (TGTX) United States $0.709B 0.00
Quanterix (QTRX) United States $0.705B 0.00
LeMaitre Vascular (LMAT) United States $0.698B 39.25
PetIQ (PETQ) United States $0.675B 16.46
Omeros (OMER) United States $0.655B 0.00
Cerus (CERS) United States $0.574B 0.00
Surmodics (SRDX) United States $0.570B 59.24
HEXO (HEXO) $0.537B 0.00
OraSure Technologies (OSUR) United States $0.492B 29.52
Owens & Minor (OMI) United States $0.474B 17.53
MacroGenics (MGNX) United States $0.474B 0.00
Organigram Holdings (OGI) Canada $0.405B 0.00
Utah Medical Products (UTMD) United States $0.396B 28.71
Meridian Bioscience (VIVO) United States $0.396B 13.62
BioLife Solutions (BLFS) United States $0.331B 134.92
Zynex (ZYXI) United States $0.329B 37.22
Bovie Medical (APYX) United States $0.275B 0.00
Neptune Wellness Solutions (NEPT) Canada $0.269B 0.00
United Health Products (UEEC) United States $0.249B 0.00
Viemed Healthcare (VMD) United States $0.242B 25.52
Vapotherm (VAPO) United States $0.227B 0.00
Repro-Med Systems (KRMD) United States $0.195B 0.00
Liberty Health Sciences (LHSIF) Canada $0.192B 0.00
Green Organic Dutchman Holdings (TGODF) Canada $0.164B 0.00
Chimerix (CMRX) United States $0.151B 0.00
Female Health (VERU) United States $0.148B 0.00
Rockwell Medical (RMTI) United States $0.141B 0.00
Cytosorbents (CTSO) United States $0.128B 0.00
Fonar (FONR) United States $0.128B 9.03
MTech Acquisition (KERN) United States $0.114B 0.00
United-Guardian (UG) United States $0.091B 23.15
Oramed Pharmaceuticals (ORMP) United States $0.080B 0.00
Nephros (NEPH) United States $0.064B 0.00
Surface Oncology (SURF) United States $0.062B 0.00
ImmuCell (ICCC) United States $0.037B 0.00
Trinity Biotech (TRIB) Ireland $0.024B 0.00
Senestech (SNES) United States $0.017B 0.00
GUARDION HEALTH (GHSI) United States $0.015B 0.00
Valeritas Holdings (VLRX) United States $0.013B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.012B 0.00
Capricor Therapeutics (CAPR) United States $0.006B 0.00
NeuroMetrix (NURO) United States $0.005B 0.00
Akers Biosciences Inc (AKER) United States $0.002B 0.00